Home > Documents in Process > DNA methylation of genes involved in lipid metabolism drives adiponectin levels and metabolic disease. > print

001     282598
005     20251210090919.0
024 7 _ |a 10.1007/s00125-025-06549-6
|2 doi
024 7 _ |a pmid:41057690
|2 pmid
024 7 _ |a 0012-186X
|2 ISSN
024 7 _ |a 1432-0428
|2 ISSN
037 _ _ |a DZNE-2025-01356
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sinke, Lucy
|0 0000-0002-9209-1266
|b 0
245 _ _ |a DNA methylation of genes involved in lipid metabolism drives adiponectin levels and metabolic disease.
260 _ _ |a Heidelberg
|c 2026
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765354076_2467
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Despite playing critical roles in the pathophysiology of type 2 diabetes and other metabolic disorders, the molecular mechanisms underlying circulating adipokine levels remain poorly understood. By identifying genomic regions involved in the regulation of adipokine levels and adipokine-mediated disease risk, we can improve our understanding of type 2 diabetes pathogenesis and inter-individual differences in metabolic risk.We conducted an epigenome-wide meta-analysis of associations between serum adiponectin (n=2791) and leptin (n=3661) and leukocyte DNA methylation at over 400,000 CpG sites across five European cohorts. The resulting methylation signatures were followed up using functional genomics, integrative analyses and causal inference methods.Our findings revealed robust associations with adiponectin at 73 CpGs and leptin at 211 CpGs. Many of the identified sites were also associated with risk factors for the metabolic syndrome and located in enhancers close to relevant transcription factor binding sites. Integrative analyses additionally linked 35 of the adiponectin-associated CpGs to the expression of 46 genes, and 100 of the leptin-associated CpGs to the expression of 151 genes, with implicated genes enriched for lipid transport (e.g. ABCG1), metabolism (e.g. CPT1A) and biosynthesis (e.g. DHCR24). Bidirectional two-sample Mendelian randomisation further identified two specific CpG sites as plausible drivers of both adiponectin levels and metabolic health: one annotated to ADIPOQ, the gene encoding adiponectin; and another linked to the expression of SREBF1, an established modifier of type 2 diabetes risk known to exert its effects via adiponectin.Taken together, these large-scale and integrative analyses uncovered links between adipokines and widespread, yet functionally specific, differences in regulation of genes with a central role in type 2 diabetes and its risk factors.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Adiponectin
|2 Other
650 _ 7 |a Causal inference
|2 Other
650 _ 7 |a Epigenomics
|2 Other
650 _ 7 |a Leptin
|2 Other
650 _ 7 |a Lipid metabolism
|2 Other
650 _ 7 |a Meta-analysis
|2 Other
650 _ 7 |a Metabolic health
|2 Other
650 _ 7 |a Type 2 diabetes
|2 Other
650 _ 7 |a Adiponectin
|2 NLM Chemicals
650 _ 7 |a Leptin
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Adiponectin: blood
|2 MeSH
650 _ 2 |a Adiponectin: genetics
|2 MeSH
650 _ 2 |a Adiponectin: metabolism
|2 MeSH
650 _ 2 |a DNA Methylation: genetics
|2 MeSH
650 _ 2 |a Lipid Metabolism: genetics
|2 MeSH
650 _ 2 |a Diabetes Mellitus, Type 2: genetics
|2 MeSH
650 _ 2 |a Diabetes Mellitus, Type 2: metabolism
|2 MeSH
650 _ 2 |a Leptin: blood
|2 MeSH
650 _ 2 |a Leptin: genetics
|2 MeSH
650 _ 2 |a CpG Islands: genetics
|2 MeSH
650 _ 2 |a Metabolic Diseases: genetics
|2 MeSH
650 _ 2 |a Metabolic Diseases: metabolism
|2 MeSH
650 _ 2 |a Genome-Wide Association Study
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
700 1 _ |a Delerue, Thomas
|0 0000-0002-6725-5361
|b 1
700 1 _ |a Wilson, Rory
|0 0000-0001-6135-3764
|b 2
700 1 _ |a Lu, Xueling
|0 0000-0001-6067-7361
|b 3
700 1 _ |a Xia, Yujing
|0 0000-0002-7746-9646
|b 4
700 1 _ |a Costeira, Ricardo
|0 0000-0002-8316-5219
|b 5
700 1 _ |a Nasr, M Kamal
|0 0009-0004-2816-7168
|b 6
700 1 _ |a Beekman, Marian
|0 0000-0003-0585-6206
|b 7
700 1 _ |a Franke, Lude
|0 0000-0002-5159-8802
|b 8
700 1 _ |a Zhernakova, Alexandra
|0 0000-0002-4574-0841
|b 9
700 1 _ |a Fu, Jingyuan
|0 0000-0001-5578-1236
|b 10
700 1 _ |a Gieger, Christian
|0 0000-0001-6986-9554
|b 11
700 1 _ |a Herder, Christian
|0 0000-0002-2050-093X
|b 12
700 1 _ |a Koenig, Wolfgang
|0 0000-0002-2064-9603
|b 13
700 1 _ |a Peters, Annette
|0 0000-0001-6645-0985
|b 14
700 1 _ |a Ordovas, José M
|0 0000-0002-7581-5680
|b 15
700 1 _ |a Dörr, Marcus
|0 0000-0001-7471-475X
|b 16
700 1 _ |a Grabe, Hans J
|0 P:(DE-2719)2811781
|b 17
700 1 _ |a Nauck, Matthias
|0 0000-0002-6678-7964
|b 18
700 1 _ |a Bell, Jordana T
|0 0000-0002-3858-5986
|b 19
700 1 _ |a Teumer, Alexander
|0 0000-0002-8309-094X
|b 20
700 1 _ |a Snieder, Harold
|0 0000-0003-1949-2298
|b 21
700 1 _ |a Waldenberger, Melanie
|0 0000-0003-0583-5093
|b 22
700 1 _ |a Slagboom, P Eline
|0 0000-0002-2875-4723
|b 23
700 1 _ |a Heijmans, Bastiaan T
|0 0000-0001-5918-0534
|b 24
773 _ _ |a 10.1007/s00125-025-06549-6
|g Vol. 69, no. 1, p. 127 - 145
|0 PERI:(DE-600)1458993-X
|n 1
|p 127 - 145
|t Diabetologia
|v 69
|y 2026
|x 0012-186X
856 4 _ |u https://pub.dzne.de/record/282598/files/DZNE-2025-01356.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/282598/files/DZNE-2025-01356.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811781
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DIABETOLOGIA : 2022
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b DIABETOLOGIA : 2022
|d 2024-12-19
920 1 _ |0 I:(DE-2719)5000001
|k AG Grabe
|l Biomarkers of Dementia in the General Population
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21